Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study

Brain

Volumn 138, Issue 10, 2015, Pages 2974-2986

  Mak, Elijah ^a   Su, Li ^a   Williams, Guy B ^b   Firbank, Michael J ^c   Lawson, Rachael A ^c   Yarnall, Alison J ^c   Duncan, Gordon W ^d   Owen, Adrian M ^e   Khoo, Tien K ^f   Brooks, David J ^g,h   Rowe, James B ^i,j,k   Barker, Roger A ^l   Burn, David J ^c   O'Brien, John T ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f GRIFFITH UNIVERSITY   (Australia)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h AARHUS UNIVERSITY   (Denmark)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j MEDICAL RESEARCH COUNCIL   (United Kingdom)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

dementia; neurodegeneration; neuroimaging; Parkinson's disease

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN CORTEX ATROPHY; BRAIN SIZE; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; BRAIN MAPPING; COGNITION DISORDERS; COMPLICATION; LONGITUDINAL STUDY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NONPARAMETRIC TEST; PATHOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN MAPPING; COGNITION DISORDERS; FEMALE; GRAY MATTER; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 84952681455     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv211     Document Type: Article

References (73)

1. Aarsland D, Andersen K, Larsen JP, Lolk A. Prevalence and characteristics of dementia in parkinson disease. Arch Neurol 2003; 60: 387-92.
2. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinsons disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866-74.
3. Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, et al. Subregional hippocampal atrophy predicts Alzheimers dementia in the cognitively normal. Neurobiol Aging 2010; 31: 1077-88.
4. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinsons disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007; 78: 254-9.
5. Burton EJ, McKeith IG, Burn DJ, OBrien JT. Brain atrophy rates in Parkinsons disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005; 20: 1571-6.
6. Burton EJ, McKeith IG, Burn DJ, Williams ED, OBrien JT. Cerebral atrophy in Parkinsons disease with and without dementia: a comparison with Alzheimers disease, dementia with Lewy bodies and controls. Brain 2004; 127: 791-800.
7. Calabresi P, Picconi B, Parnetti L, Di Filippo M. A convergent model for cognitive dysfunctions in Parkinsons disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 2006; 5: 974-83.
8. Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinsons disease. Neurology 1997; 49: 1570-6.
9. Dalaker TO, Zivadinov R, Larsen JP, Beyer MK, Cox JL, Alves G, et al. Gray matter correlations of cognition in incident Parkinsons disease. Mov Disord 2010; 25: 629-33.
10. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717-25.
11. de Jong LW, Wang Y, White LR, Yu B, van Buchem MA, Launer LJ. Ventral striatal volume is associated with cognitive decline in older people: a population based MR-study. Neurobiol Aging 2012; 33s: 424.e1-10.
12. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384-6.
13. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 2000; 97: 11050-5.
14. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999; 9: 195-207.
15. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
16. Foltynie T, Brayne CEG, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinsons patients in the UK. The CamPaIGN study. Brain 2004; 127: 550-60.
17. Fray PJ, Robbins TW. CANTAB battery: proposed utility in neurotoxicology. Neurotoxicol Teratol 1996; 18: 499-504.
18. Garcia-Diaz AI, Segura B, Baggio HC, Marti MJ, Valldeoriola F, Compta Y, et al. Structural MRI correlates of the MMSE and pentagon copying test in Parkinsons disease. Parkinsonism Relat Disord 2014; 20: 1405-10.
19. Garcia-Garcia D, Clavero P, Gasca Salas C, Lamet I, Arbizu J, Gonzalez-Redondo R, et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinsons disease. Eur J Nucleic Med Mol Imaging 2012; 39: 1767-77.
20. Goetz CG, Nutt JG, Stebbins GT. The unified dyskinesia rating scale: presentation and clinimetric profile. Mov Disord 2008; 23: 2398-403.
21. Hagler DJ, Saygin AP, Sereno MI. Smoothing and cluster thresholding for cortical surface-based group analysis of fMRI data. Neuroimage 2006; 33: 1093-103.
22. Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine A-L, Soland V, et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinsons disease longitudinally. Brain 2014; 137: 1120-9.
23. Hanganu A, Bedetti C, Jubault T, Gagnon JF, Mejia-Constain B, Degroot C, et al. Mild cognitive impairment in patients with Parkinsons disease is associated with increased cortical degeneration. Mov Disord 2013; 28: 1360-9.
24. Hattori T, Orimo S, Aoki S, Ito K, Abe O, Amano A, et al. Cognitive status correlates with white matter alteration in Parkinsons disease. Hum Brain Mapp 2012; 33: 727-39.
25. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-22.
26. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology 2001; 57: S11-26.
27. Hughes AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-70.
28. Hwang KS, Beyer MK, Green AE, Chung C, Thompson PM, Janvin C, et al. Mapping cortical atrophy in Parkinsons disease patients with dementia. J Parkinsons Dis 2013; 3: 69-76.
29. Ibarretxe-Bilbao N, Junque C, Segura B, Baggio HC, Marti MJ, Valldeoriola F, et al. Progression of cortical thinning in early Parkinsons disease. Mov Disord 2012; 27: 1746-53.
30. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinsons disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005; 18: 149-54.
31. Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinsons disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009; 15: 88-93.
32. Jubault T, Gagnon J-F, Karama S, Ptito A, Lafontaine A-L, Evans AC, et al. Patterns of cortical thickness and surface area in early Parkinsons disease. Neuroimage 2011; 55: 462-7.
33. Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinsons disease: the dual syndrome hypothesis. Neurodegener Dis 2012; 11: 79-92.
34. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, OBrien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013; 80: 276-81.
35. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885-92.
36. Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, et al. Quality of life and mild cognitive impairment in early parkinsons disease: does subtype matter? J Parkinsons Dis 2014: 1-6.
37. Lee HM, Kwon K-Y, Kim M-J, Jang J-W, Suh S-I, Koh S-B, et al. Subcortical grey matter changes in untreated, early stage Parkinsons disease without dementia. Parkinsonism Relat Disord 2014; 20: 622-6.
38. Lee JE, Cho KH, Song SK, Kim HJ, Lee HS, Sohn YH, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinsons disease. J Neurol Neurosurg Psychiatry 2014; 85: 7-16.
39. Leh SE, Ptito A, Chakravarty MM, Strafella AP. Fronto-striatal connections in the human brain: a probabilistic diffusion tractography study. Neurosci Lett 2007; 419: 113-8.
40. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinsons disease: movement disorder society task force guidelines. Mov Disord 2012; 27: 349-56.
41. Mak E, Bergsland N, Dwyer MG, Zivadinov R, Kandiah N. Subcortical atrophy is associated with cognitive impairment in mild parkinson disease: a combined investigation of volumetric changes, cortical thickness, and vertex-based shape analysis. Am J Neuroradiol 2014; 35: 2257-64.
42. Mak E, Su L, Williams GB, Watson R, Firbank MJ, Blamire AM, et al. Progressive cortical thinning and subcortical atrophy in dementia with Lewy bodies and Alzheimers disease. Neurobiol Aging 2015; 36: 1743-50.
43. Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, et al. Dopaminergic modulation of cortical function in patients with Parkinsons disease. Ann Neurol 2002; 51: 156-64.
44. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, et al. Grey matter atrophy in cognitively impaired Parkinsons disease. J Neurol Neurosurg Psychiatry 2012; 83: 188-94.
45. Monastero R, Di Fiore P, Ventimiglia GD, Camarda R, Camarda C. The neuropsychiatric profile of Parkinsons disease subjects with and without mild cognitive impairment. J Neural Transm 2013; 120: 607-11.
46. Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinsons disease: ICICLE-PD study. Brain 2014; 137: 2743-58.
47. Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, et al. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinsons disease. PLoS One 2013; 8: e54980.
48. Pedersen KF, Larsen JP, Tysnes O-B, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013; 70: 580-6.
49. Pereira JB, Ibarretxe-bilbao N, Marti M, Bargallo N, Compta Y, Junque C. Assessment of cortical degeneration in patients with Parkinson s disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp 2012; 33: 2521-34.
50. Pereira JB, Svenningsson P, Weintraub D, Brnick K, Lebedev A, Westman E, et al. Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology 2014; 82: 2017-25.
51. Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry 2009; 166: 702-10.
52. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinsons patients with neural transplants. Sci Transl Med 2010; 2: 38ra46.
53. Polito C, Berti V, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinsons disease. Neurobiol Aging 2012; 33: 206.e29-e39.
54. Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, Rowe JB. White matter pathology in Parkinsons disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage 2012; 62: 1675-84.
55. Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinsons disease. Mov Disord 2012; 27: 1392-7.
56. Reuter M, Fischl B. Avoiding asymmetry-induced bias in longitudinal image processing. Neuroimage 2011; 57: 19-21.
57. Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage 2010; 53: 1181-96.
58. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012; 61: 1402-18.
59. Rowe JB, Hughes L, Williams-Gray CH, Bishop S, Fallon S, Barker RA, et al. The val158met COMT polymorphisms effect on atrophy in healthy aging and Parkinsons disease. Neurobiol Aging 2010; 31: 1064-8.
60. Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RSR, Busa E, et al. Thinning of the cerebral cortex in aging. Cereb Cortex 2004; 14: 721-30.
61. Segura B, Baggio HC, Marti MJ, Valldeoriola F, Compta Y, Garcia-Diaz AI, et al. Cortical thinning associated with mild cognitive impairment in Parkinsons disease. Mov Disord 2014; 29: 1-9.
62. Simons JS, Spiers HJ. Prefrontal and medial temporal lobe interactions in long-term memory. Nat Rev Neurosci 2003; 4: 637-48.
63. Song SK, Lee JE, Park H, Sohn YH, Lee JD. The pattern of cortical atrophy in patients with Parkinsons disease according to cognitive status. Mov Disord 2011; 26: 289-96.
64. Tinaz S, Courtney MG, Stern CE, Phil D. Focal cortical and subcortical atrophy in early Parkinsons disease. Mov Disord 2011; 26: 436-41.
65. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinsons disease. Mov Disord 2010; 25: 2649-53.
66. Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf AD, Duda JE, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011; 68: 1562-8.
67. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002; 13: 183-92.
68. Whitwell JL, Jack CR, Przybelski SA, Parisi JE, Senjem ML, Boeve BF, et al. Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis. Neurobiol Aging 2011; 32: 1531-41.
69. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinsons disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958-69.
70. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinsons disease cohort. Brain 2007; 130: 1787-98.
71. Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014; 82: 308-16.
72. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17: 37-49.
73. Zarei M, Ibarretxe-Bilbao N, Compta Y, Hough M, Junque C, Bargallo N, et al. Cortical thinning is associated with disease stages and dementia in Parkinsons disease. J Neurol Neurosurg Psychiatry 2013; 84: 875-81.